ClinicalTrials.gg
WithdrawnNCT01501461Updated Apr 19, 2018

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome

An interventional study of Harvesting and implantation of stem cells in Frailty Syndrome, sponsored by Ageless Regenerative Institute. Withdrawn at 1 site in Mexico. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-04-19.

Sponsored by Ageless Regenerative Institute · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Company dissolved
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
55 Years to 90 Years
Sex
All
01

Study summary

The intent of this clinical study is to answer the questions:

  1. Is the proposed treatment safe
  2. Is treatment effective in improving the health of patients with human frailty syndrome.
Read the detailed description

This will be an open-label, non-randomized multi-center patient sponsored study of Autologous Adipose-Derived Stem Cells (ASC) implantation after liposuction using an IV delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered intravenously.

02

Conditions studied

  • Frailty Syndrome

Browse trials for

03

In context

Frailty

1,284 studies on the registry are indexed under Frailty; 452 are open to participants now.

Browse Frailty studies →

Lead sponsor

Ageless Regenerative Institute is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and Females Age >55.
  • Frailty syndrome defined by:

BMD\< T-1 (Based on QCT results) Body Mass: males \<8% or >17% fat, females\<10% or>24% fat (Lean Body Mass=Total Body Mass- %Body Fat)

  • Ability to participate in the short physical performance battery
  • Up to date on all age and gender appropriate cancer screening per American Cancer Society

Exclusion criteria

Exclusion Criteria:

  • \< 6 months due to concomitant illnesses.
  • Exposure to any drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
  • Active infectious disease patients known to have tested positive for , HTLV, , , CMV (IgM > IgG) and/or syphilis. will have an expert consulted as to patient eligibility based on the patient's infectious status
  • Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
  • Patients on chronic transplant therapy
  • Active clinical infection being treated by antibiotics within one week of enrollment.
  • Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
  • History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
  • Unwilling and/or not able to give written .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Interventions

  • ProcedureHarvesting and implantation of stem cells

    The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.

06

What researchers measure

Primary outcomes

  1. Improvement in Physical Performance Test (PPT) Results

    Time frame: 3 months

  2. Number of Adverse Events Reported

    The safety of adipose-derived stem cell injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study injection and up to the 6-month period following treatment.

    Time frame: up to 6 months

  3. Improvement in Physical Performance Test (PPT) Results

    Time frame: 6 months

  4. Improved body composition/bone density compared to baseline

    Time frame: 3 months

  5. Improved body composition/bone density compared to baseline

    Time frame: 6 months

  6. Quality of life is improved compared to baseline

    Time frame: 3 months

  7. Quality of life is improved compared to baseline

    Time frame: 6 months

Secondary outcomes

  1. Improved exercise capacity compared to baseline

    Time frame: 3 months

  2. Improved exercise capacity compared to baseline

    Time frame: 6 months

07

Study locations

1 site
  • Instituto de Medicina Regenerativa
    Tijuana, Baja California 22010, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of May 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2011
First posted
Dec 29, 2011
Start
May 1, 2011
Primary completionActual
May 30, 2017
CompletionActual
Jun 30, 2017
Last update
Apr 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01501461
Lead sponsor
Ageless Regenerative Institute
Collaborators
Instituto de Medicina Regenerativa
Responsible party
Sponsor
First posted
Dec 29, 2011
Start date
May 1, 2011
Primary completion
May 30, 2017
Completion
Jun 30, 2017
Last update
Apr 19, 2018

Study contacts

Clemente Zuniga, MD
principal investigator · Instituto de Medicina Regenerativa
Jesus A Perez, MD
principal investigator · Instituto de Medicina Regenerativa

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion